Altimmune announced its Q3 2026 financial results, highlighting progress in its liver disease drug pemvidutide. The Phase 3 PERFORMA trial for metabolic dysfunction-associated steatohepatitis (MASH) is advancing as planned, with topline data expected in 2029. Positive Phase 2 results for alcohol use disorder (AUD) were presented, and an FDA End-of-Phase 2 meeting is scheduled for December 2026 to discuss a Phase 3 program. The company holds $480 million in cash and investments, supporting ongoing trials and development.
Altimmune's Q3 2026 financial results and business update provide context for readers, with Pluang's Health-sector market snapshot as of Nov 12, 2026 19:11 WIB showing 91 of 150 US health stocks rising and 53 falling. Notable movers include MRVI at USD 7.94 with a 3.12% increase and a Pluang order activity of 55% Sell / 45% Buy, TWST at USD 118.77 down 3.12% but with 100% Buy orders, and INO at USD 1.43 down 3.05% with 58% Sell orders. The most notable figure is TWST's 100% Buy order activity.
Evaxion, a clinical-stage TechBio company, has released its financial calendar for 2027, outlining important dates for business updates and financial results. Key events include the full year 2026 results on March 4, the Annual General Meeting on Apr...
CollPlant Biotechnologies will change its Nasdaq ticker from CLGN to OPHI starting November 13, 2026, reflecting its strategic shift toward photonic computing through its subsidiary LightSolver. This move highlights CollPlant's focus on developing Li...
Glider has introduced a global investing platform for tokenized stocks that operates permissionlessly, bypassing the SEC's Tokenized Securities Venues (TSVs) which 50 public companies recently rejected. Backed by major investors like a16z and Coinbas...
BofA Securities raised its price target for Royal Caribbean Group to $365, citing strong booking volumes and the company’s goal of adjusted earnings per share around $20 by 2027. The cruise operator expects 4.5% capacity growth next year and has repo...
Tilray Brands announced that its subsidiaries 10 Barrel Brewing, Widmer Brothers Brewing, and Hop Valley Brewing are now the official craft beer partners of the Portland Trail Blazers. This partnership expands the availability of Oregon craft beers a...
